Trazodone: Effective Relief for Depression and Sleep Disorders
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.76 | $45.58 (0%) | 🛒 Add to cart |
| 90 | $0.70 | $68.37 $62.78 (8%) | 🛒 Add to cart |
| 120 | $0.67 | $91.16 $79.98 (12%) | 🛒 Add to cart |
| 180 | $0.64 | $136.74 $115.24 (16%) | 🛒 Add to cart |
| 270 | $0.62 | $205.11 $166.84 (19%) | 🛒 Add to cart |
| 360 | $0.61
Best per pill | $273.48 $218.44 (20%) | 🛒 Add to cart |
Synonyms | |||
Trazodone is a multifunctional antidepressant medication belonging to the serotonin antagonist and reuptake inhibitor (SARI) class. It is primarily indicated for the treatment of major depressive disorder (MDD) and is widely utilized off-label for the management of insomnia due to its sedative properties. With a well-established efficacy profile and a favorable side effect spectrum compared to many traditional antidepressants, trazodone offers clinicians a versatile therapeutic option. Its dual mechanism of action modulates serotonin pathways, addressing both mood dysregulation and sleep architecture disturbances.
Features
- Active ingredient: Trazodone hydrochloride
- Available formulations: Oral tablets (50 mg, 100 mg, 150 mg, 300 mg) and extended-release tablets
- Pharmacologic class: Serotonin antagonist and reuptake inhibitor (SARI)
- Half-life: Approximately 5–9 hours for immediate-release; 7–10 hours for extended-release
- Bioavailability: ~65–80% with oral administration
- Metabolism: Hepatic, primarily via CYP3A4 isoenzyme
- Excretion: Renal (70–75%) and fecal (20–25%)
Benefits
- Effectively alleviates symptoms of major depressive disorder, including low mood, anhedonia, and psychomotor retardation
- Promotes improved sleep onset and maintenance through sedative effects at lower doses
- Exhibits a lower incidence of sexual dysfunction compared to SSRIs and SNRIs
- Lacks significant anticholinergic side effects, reducing risks such as dry mouth and constipation
- May reduce anxiety symptoms often comorbid with depression
- Provides flexible dosing options for individualized treatment regimens
Common use
Trazodone is FDA-approved for the treatment of major depressive disorder (MDD) in adults. Its off-label applications are extensive and evidence-supported, particularly for insomnia management, where lower doses are typically employed. Clinicians frequently prescribe trazodone for anxiety disorders, including generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD), often as an adjunctive therapy. It may also be used in certain cases of fibromyalgia and neuropathic pain due to its effects on central pain modulation pathways. The medication is sometimes utilized in veterinary medicine for behavioral disorders in dogs and cats.
Dosage and direction
For depression treatment in adults, the initial dosage is typically 150 mg per day in divided doses, which may be increased by 50 mg per day every 3–4 days based on therapeutic response and tolerability. The maximum recommended dose is 400 mg per day for outpatients and 600 mg per day for inpatients. For insomnia, doses typically range from 25 mg to 100 mg administered at bedtime. Extended-release formulations should be taken once daily, preferably with food to enhance absorption and minimize side effects. Dosage adjustments are necessary for elderly patients and those with hepatic or renal impairment. Treatment should be initiated under medical supervision, with regular monitoring of therapeutic response and adverse effects.
Precautions
Patients should be cautioned about the potential for drowsiness, dizziness, or impaired coordination, particularly during the initial treatment phase. Orthostatic hypotension may occur, especially in elderly patients or those taking antihypertensive medications. Regular monitoring of complete blood count is advised during prolonged therapy due to rare reports of leukopenia and neutropenia. Priapism, while uncommon, represents a medical emergency requiring immediate attention. Patients with a history of cardiac disease should undergo baseline and periodic cardiovascular assessment. Abrupt discontinuation should be avoided; gradual tapering is recommended to prevent withdrawal symptoms. Alcohol consumption should be avoided due to additive CNS depression effects.
Contraindications
Trazodone is contraindicated in patients with known hypersensitivity to trazodone or any component of the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to risk of serotonin syndrome; a minimum 14-day washout period should be observed when switching between these medications. It should not be administered to patients in the acute recovery phase following myocardial infarction. Severe hepatic impairment represents a contraindication due to altered metabolism and elimination. The medication is not recommended during the initial postpartum period for breastfeeding mothers without careful risk-benefit assessment.
Possible side effects
Common adverse reactions (≥5%) include somnolence, dizziness, headache, dry mouth, nausea, and blurred vision. Less frequent side effects (1–5%) may include constipation, fatigue, nervousness, hypotension, and weight changes. Rare but serious adverse events (<1%) include priapism, serotonin syndrome, QT prolongation, suicidal ideation (particularly in young adults), and blood dyscrasias. Extrapyramidal symptoms, although uncommon, have been reported. Most side effects are dose-dependent and often diminish with continued therapy. Patients should report any persistent or severe adverse effects to their healthcare provider promptly.
Drug interaction
Trazodone exhibits significant interactions with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) which may increase serum concentrations and toxicity risk. Concomitant use with other serotonergic agents (SSRIs, SNRIs, triptans) increases the risk of serotonin syndrome. Enhanced sedation may occur with CNS depressants including alcohol, benzodiazepines, and opioids. Trazodone may potentiate the effects of antihypertensive medications and increase the risk of hypotension. Concurrent administration with drugs that prolong QT interval (e.g., antipsychotics, antiarrhythmics) requires careful monitoring. Warfarin efficacy may be altered, necessitating INR monitoring. Digoxin levels may be increased with concomitant use.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is接近 the time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling doses to compensate for a missed dose is not recommended due to increased risk of adverse effects. Patients using the extended-release formulation should not crush or chew tablets to make up for missed doses. Consistent daily administration at approximately the same time(s) is recommended to maintain steady-state concentrations. Healthcare providers should be consulted if multiple doses are missed or if a new dosing schedule is needed.
Overdose
Trazodone overdose may manifest as excessive sedation, respiratory depression, hypotension, nausea, and vomiting. Severe overdose may lead to priapism, seizures, serotonin syndrome, or cardiac arrhythmias. There is no specific antidote; management involves supportive care and symptomatic treatment. Gastric lavage may be considered if presentation occurs within 1-2 hours of ingestion. Activated charcoal may be administered. Cardiovascular monitoring should be instituted, with particular attention to QT interval. Forced diuresis, dialysis, or hemoperfusion are not effective due to trazodone’s high protein binding and extensive tissue distribution. Medical attention should be sought immediately for suspected overdose.
Storage
Store at controlled room temperature (20–25°C or 68–77°F) in the original container, protected from light and moisture. Keep tightly closed and away from excessive heat or humidity. Do not store in bathroom cabinets where moisture levels may fluctuate. Keep all medications out of reach of children and pets. Dispose of unused or expired medication through medication take-back programs or according to FDA-recommended disposal methods. Do not flush medications down the toilet unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual response to medication may vary. Always consult with a qualified healthcare professional before starting, changing, or discontinuing any medication. The prescribing physician should be aware of the patient’s complete medical history, current medications, and specific health conditions. This information is not exhaustive and does not replace professional medical judgment. Emergency medical attention should be sought for serious adverse reactions or overdose situations.
Reviews
Clinical studies demonstrate trazodone’s efficacy in depression treatment with response rates comparable to other antidepressants. Meta-analyses support its off-label use for insomnia, showing significant improvement in sleep parameters. Patient reports frequently note improved sleep quality and mood stabilization, though some report residual morning drowsiness. Long-term studies indicate maintained efficacy with appropriate dosing adjustments. Comparative analyses show favorable tolerability versus tricyclic antidepressants. The medication receives generally positive evaluations in clinical practice guidelines for both primary and adjunctive use in mood and sleep disorders.